BioSpace News Archive

Mainz Biomed N.V. announced today groundbreaking topline results from its eAArly DETECT U.S. clinical study, a multi-center feasibility study assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into a next generation version of ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories.

NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH-funded clinical trial of Quell titled “Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial.”

EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.

Arvinas, Inc. announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. to discuss vepdegestrant data presented at the 2023 San Antonio Breast Cancer Symposium as well as plans to expand the vepdegestrant development program.